<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03369002</url>
  </required_header>
  <id_info>
    <org_study_id>CB8025-11732</org_study_id>
    <nct_id>NCT03369002</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy Subjects</brief_title>
  <official_title>A Phase 1, Open Label, Non-Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Oral Seladelpar in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects With Normal Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CymaBay Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CymaBay Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1 open label study is being conducted to directly characterize the pharmacokinetic
      (PK) profiles of seladelpar following administration of a single oral dose in subjects with
      varying degrees of hepatic impairment (HI) compared to healthy matched control subjects with
      normal hepatic function.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 27, 2017</start_date>
  <completion_date type="Actual">May 15, 2018</completion_date>
  <primary_completion_date type="Actual">May 15, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach maximum concentration (Tmax)</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under of the curve (AUC0-t and AUC0-∞)</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination of half-life (t1/2)</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal elimination rate constant (λz)</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total body clearance (CL/F)</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of distribution (Vz/F)</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Normal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Child-Pugh Score: N/A
Subjects will receive a single 10 mg oral dose of seladelpar</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Child-Pugh Score: A (5 to 6 points)
Subjects will receive a single 10 mg oral dose of seladelpar</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Child-Pugh Score: B (7 to 9 points)
Subjects will receive a single 10 mg oral dose of seladelpar</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Child-Pugh Score: C (10 to 15 points)
Subjects will receive a single 10 mg oral dose of seladelpar</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>seladelpar</intervention_name>
    <description>Oral single dose 10 mg</description>
    <arm_group_label>Normal</arm_group_label>
    <arm_group_label>Mild Impairment</arm_group_label>
    <arm_group_label>Moderate Impairment</arm_group_label>
    <arm_group_label>Severe Impairment</arm_group_label>
    <other_name>MBX-8025</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have given written informed consent (signed and dated) and any authorizations
             required by local law.

          -  Willing to be confined to CRU for the entire duration required by the protocol.

          -  Male or female, between 18 and 80 years of age.

          -  Healthy subject with normal liver function must be non-smoker and no use of other
             tobacco or nicotine-containing products. Subject with HI must be non-smoker, or smoke
             ≤10 cigarettes per day during the study.

          -  Healthy subject must not be taking any prescribed or non-prescribed medications unless
             permitted. Subject with HI will be allowed to take their chronic medications unless
             excluded by the protocol.

        Exclusion Criteria:

          -  Pregnant or lactating women.

          -  Treatment with another investigational drug or device within 30 days prior to study
             drug administration.

          -  Has donated or lost a significant volume of blood within 56 days or plasma within 7
             days prior to Check-in day.

          -  Inability to swallow medication.

          -  Positive test for drugs of abuse and/or positive alcohol test at Screening or Day -1.

          -  Positive test at Screening for HBsAg, hepatitis C virus (HCV), or HIV.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vrg &amp; Noccr</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2017</study_first_submitted>
  <study_first_submitted_qc>December 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2017</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatic Impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

